Emerging influenza viruses and the prospect of a universal influenza virus vaccine

Biotechnology Journal

Volumn 10, Issue 5, 2015, Pages 690-701

  Krammer, Florian ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Avian influenza; Heterosubtypic immunity; Pandemic influenza; Universal influenza virus vaccine; Zoonotic influenza

Indexed keywords

VACCINES;

AVIAN INFLUENZA; HETEROSUBTYPIC IMMUNITY; INFLUENZA VIRUS; PANDEMIC INFLUENZA; ZOONOTIC INFLUENZA;

VIRUSES;

DNA VACCINE; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; VIRUS VECTOR;

ANTIBODY RESPONSE; ASYMPTOMATIC INFECTION; IMMUNE RESPONSE; IMMUNITY; INFLUENZA A (H2N2); INFLUENZA A (H3N2); INFLUENZA VIRUS; INFLUENZA VIRUS A H10N7; INFLUENZA VIRUS A H10N8; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H7N3; INFLUENZA VIRUS A H7N9; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; REVIEW; SEASONAL INFLUENZA; VACCINE PRODUCTION; VIRUS STRAIN; VIRUS TRANSMISSION; ANIMAL; BIOSYNTHESIS; CLASSIFICATION; HUMAN; IMMUNOLOGY; INFLUENZA A VIRUS; INFLUENZA, HUMAN; INFLUENZAVIRUS B; ORTHOMYXOVIRIDAE INFECTIONS; PANDEMIC; TRANSMISSION; VETERINARY; ZOONOSES;

AVES; ORTHOMYXOVIRIDAE; SWINE INFLUENZA VIRUS;

ANIMALS; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INFLUENZAVIRUS B; ORTHOMYXOVIRIDAE INFECTIONS; PANDEMICS; ZOONOSES;

EID: 84928825136     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201400393     Document Type: Review

References (141)

1. Krammer, F., Palese, P., Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr. Opin. Virol. 2013, 3, 521-530.
2. de Jong, J. C., Beyer, W. E., Palache, A. M., Rimmelzwaan, G. F., Osterhaus, A. D., Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J. Med. Virol. 2000, 61, 94-99.
3. Tricco, A. C., Chit, A., Soobiah, C., Hallett, D. et al., Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 2013, 11, 153.
4. Rolfes, M., Blanton, L., Brammer, L., Smith, S. et al., Update: Influenza activity - United States, september 28-december 6, 2014. MMWR Morb. Mortal Wkly. Rep. 2014, 63, 1189-1194.
5. Claas, E. C., Osterhaus, A. D., van Beek, R., De Jong, J. C. et al., Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998, 351, 472-477.
6. Wang, T. T., Parides, M. K., Palese, P., Seroevidence for H5N1 influenza infections in humans: meta-analysis. Science 2012, 335, 1463.
7. Morens, D. M., Taubenberger, J. K., How low is the risk of influenza A(H5N1) infection? J. Infect. Dis. 2014.
8. Gomaa, M. R., Kayed, A. S., Elabd, M. A., Zeid, D. A. et al., Avian influenza A(H5N1) and A(H9N2) seroprevalence and risk factors for infection among Egyptians: A prospective, controlled seroepidemiological study. J. Infect. Dis. 2014.
9. Zhao, K., Gu, M., Zhong, L., Duan, Z. et al., Characterization of three H5N5 and one H5N8 highly pathogenic avian influenza viruses in China. Vet. Microbiol. 2013, 163, 351-357.
10. Ku, K. B., Park, E. H., Yum, J., Kim, J. A. et al., Highly pathogenic avian influenza A(H5N8) virus from waterfowl, South Korea, 2014. Emerg. Infect. Dis. 2014, 20, 1587-1588.
11. Jeong, J., Kang, H. M., Lee, E. K., Song, B. M. et al., Highly pathogenic avian influenza virus (H5N8) in domestic poultry and its relationship with migratory birds in South Korea during 2014. Vet. Microbiol. 2014, 173, 249-257.
12. Avian influenza outbreak in Yorkshire: Strain identified as H5N8. Vet. Rec. 2014, 175, 495-496.
13. Fan, S., Zhou, L., Wu, D., Gao, X. et al., A novel highly pathogenic H5N8 avian influenza virus isolated from a wild duck in China. Influenza Other Respir. Viruses 2014, 8, 646-653.
14. Wu, H., Peng, X., Xu, L., Jin, C. et al., Novel reassortant influenza A(H5N8) viruses in domestic ducks, eastern China. Emerg. Infect. Dis. 2014, 20, 1315-1318.
15. Lee, Y. J., Kang, H. M., Lee, E. K., Song, B. M. et al., Novel reassortant influenza A(H5N8) viruses, South Korea, 2014. Emerg. Infect. Dis. 2014, 20, 1087-1089.
16. Song, B., Kang, H., Lee, E., Jeong, J. et al., Pathogenicity of H5N8 highly pathogenic avian influenza virus in chickens, South Korea, 2014. J. Vet. Sci. 2014.
17. Gao, R., Cao, B., Hu, Y., Feng, Z. et al., Human infection with a novel avian-origin influenza A (H7N9) virus. N. Engl. J. Med. 2013, 368, 1888-1897.
18. Pantin-Jackwood, M. J., Miller, P. J., Spackman, E., Swayne, D. E. et al., Role of poultry in the spread of novel H7N9 influenza virus in China. J. Virol. 2014, 88, 5381-5390.
19. Hu, J., Zhu, Y., Zhao, B., Li, J. et al., Limited human-to-human transmission of avian influenza A(H7N9) virus, Shanghai, China, March to April 2013. Euro. Surveill. 2014, 19.
20. Wei, S. H., Yang, J. R., Wu, H. S., Chang, M. C. et al., Human infection with avian influenza A H6N1 virus: an epidemiological analysis. Lancet Respir. Med. 2013, 1, 771-778.
21. Yuan, J., Zhang, L., Kan, X., Jiang, L. et al., Origin and molecular characteristics of a novel 2013 avian influenza A(H6N1) virus causing human infection in Taiwan. Clin. Infect. Dis. 2013, 57, 1367-1368.
22. Shi, W., Shi, Y., Wu, Y., Liu, D., Gao, G. F., Origin and molecular characterization of the human-infecting H6N1 influenza virus in Taiwan. Protein Cell 2013, 4, 846-853.
23. Wang, G., Deng, G., Shi, J., Luo, W. et al., H6 influenza viruses pose a potential threat to human health. J. Virol. 2014, 88, 3953-3964.
24. Zhang, G., Kong, W., Qi, W., Long, L. P. et al., Identification of an H6N6 swine influenza virus in southern China. Infect. Genet. Evol. 2011, 11, 1174-1177.
25. Beare, A. S., Webster, R. G., Replication of avian influenza viruses in humans. Arch. Virol. 1991, 119, 37-42.
26. Chen, H., Yuan, H., Gao, R., Zhang, J. et al., Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study. Lancet 2014, 383, 714-721.
27. García-Sastre, A., Schmolke, M., Avian influenza A H10N8 - a virus on the verge? Lancet 2014, 383, 676-677.
28. Zohari, S., Neimanis, A., Harkonen, T., Moraeus, C., Valarcher, J., Avian influenza A(H10N7) virus involvement in mass mortality of harbour seals (Phoca vitulina) in Sweden, March through October 2014. Euro. Surveill. 2014, 19.
29. Su, S., Qi, W., Zhou, P., Xiao, C. et al., First Evidence of H10N8 Avian Influenza Virus Infections among Feral Dogs in Live Poultry Markets in Guangdong Province, China. Clin. Infect. Dis. 2014.
30. Qi, W., Zhou, X., Shi, W., Huang, L. et al., Genesis of the novel human-infecting influenza A(H10N8) virus and potential genetic diversity of the virus in poultry, China. Euro. Surveill. 2014, 19.
31. Zhou, H., Cao, Z., Tan, L., Fu, X. et al., Avian-like A (H1N1) swine influenza virus antibodies among swine farm residents and pigs in southern China. Jpn. J. Infect. Dis. 2014, 67, 184-190.
32. Qi, X., Cui, L., Jiao, Y., Pan, Y. et al., Antigenic and genetic characterization of a European avian-like H1N1 swine influenza virus from a boy in China in 2011. Arch. Virol. 2013, 158, 39-53.
33. Liang, H., Lam, T. T., Fan, X., Chen, X. et al., Expansion of genotypic diversity and establishment of 2009 H1N1 pandemic-origin internal genes in pigs in China. J. Virol. 2014, 88, 10864-10874.
34. Chou, Y. Y., Albrecht, R. A., Pica, N., Lowen, A. C. et al., The M segment of the 2009 new pandemic H1N1 influenza virus is critical for its high transmission efficiency in the guinea pig model. J. Virol. 2011, 85, 11235-11241.
35. Campbell, P. J., Danzy, S., Kyriakis, C. S., Deymier, M. J. et al., The M segment of the 2009 pandemic influenza virus confers increased neuraminidase activity, filamentous morphology, and efficient contact transmissibility to A/Puerto Rico/8/1934-based reassortant viruses. J. Virol. 2014, 88, 3802-3814.
36. Ma, W., Vincent, A. L., Gramer, M. R., Brockwell, C. B. et al., Identification of H2N3 influenza A viruses from swine in the United States. Proc. Natl. Acad. Sci. USA 2007, 104, 20949-20954.
37. Palese, P., Wang, T. T., Why do influenza virus subtypes die out? A hypothesis. mBio 2011, 2.
38. Nabel, G. J., Wei, C. J., Ledgerwood, J. E., Vaccinate for the next H2N2 pandemic now. Nature 2011, 471, 157-158.
39. (CDC), C. f. D. C. a. P., Notes from the field: Outbreak of influenza A (H3N2) virus among persons and swine at a county fair - Indiana, July 2012. MMWR Morb. Mortal Wkly. Rep. 2012, 61, 561.
40. (CDC), C. f. D. C. a. P., Update: Influenza A (H3N2)v transmission and guidelines - five states, 2011. MMWR Morb. Mortal Wkly. Rep. 2012, 60, 1741-1744.
41. Anthony, S. J., St Leger, J. A., Pugliares, K., Ip, H. S. et al., Emergence of fatal avian influenza in New England harbor seals. mBio 2012, 3, e00166-00112.
42. Skowronski, D. M., Janjua, N. Z., De Serres, G., Purych, D. et al., Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v). J. Infect. Dis. 2012, 206, 1852-1861.
43. (CDC), C. f. D. C. a. P., Notes from the Field: Highly Pathogenic Avian Influenza A (H7N3) Virus Infection in Two Poultry Workers - Jalisco, Mexico, July 2012. MMWR Morb. Mortal. Wkly. Rep. 2012, 61, 726-727.
44. Tong, S., Li, Y., Rivailler, P., Conrardy, C. et al., A distinct lineage of influenza A virus from bats. Proc. Natl. Acad. Sci. USA 2012, 109, 4269-4274.
45. Tong, S., Zhu, X., Li, Y., Shi, M. et al., New world bats harbor diverse influenza A viruses. PLoS Pathog. 2013, 9, e1003657.
46. Juozapaitis, M., Aguiar Moreira, E., Mena, I., Giese, S. et al., An infectious bat-derived chimeric influenza virus harbouring the entry machinery of an influenza A virus. Nat. Commun. 2014, 5, 4448.
47. Tambyah, P. A., Wilder-Smith, A., Pavlova, B. G., Barrett, P. N. et al., Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine. Vaccine 2012, 30, 329-335.
48. Barrett, P. N., Mundt, W., Kistner, O., Howard, M. K., Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev. Vaccines 2009, 8, 607-618.
49. Dormitzer, P. R., Rapid production of synthetic influenza vaccines. Curr. Top. Microbiol. Immunol. 2015, 386, 237-273.
50. Cox, R. J., Madhun, A. S., Hauge, S., Sjursen, H. et al., A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 2009, 27, 1889-1897.
51. Perdue, M. L., Arnold, F., Li, S., Donabedian, A. et al., The future of cell culture-based influenza vaccine production. Expert Rev. Vaccines 2011, 10, 1183-1194.
52. Ehrlich, H. J., Berezuk, G., Fritsch, S., Aichinger, G. et al., Clinical development of a Vero cell culture-derived seasonal influenza vaccine. Vaccine 2012, 30, 4377-4386.
53. Dormitzer, P. R., Suphaphiphat, P., Gibson, D. G., Wentworth, D. E. et al., Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci. Transl. Med. 2013, 5, 185ra168.
54. Bart, S. A., Hohenboken, M., Della Cioppa, G., Narasimhan, V. et al., A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults. Sci. Transl. Med. 2014, 6, 234ra255.
55. Cox, M. M., Recombinant protein vaccines produced in insect cells. Vaccine 2012, 30, 1759-1766.
56. Stevens, J., Chen, L. M., Carney, P. J., Garten, R. et al., Receptor specificity of influenza A H3N2 viruses isolated in mammalian cells and embryonated chicken eggs. J. Virol. 2010, 84, 8287-8299.
57. Krammer, F., Grabherr, R., Alternative influenza vaccines made by insect cells. Trends Mol. Med. 2010, 16, 313-320.
58. Klausberger, M., Wilde, M., Palmberger, D., Hai, R. et al., One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge. Vaccine 2014, 32, 355-362.
59. Smith, G. E., Flyer, D. C., Raghunandan, R., Liu, Y. et al., Development of influenza H7N9 virus like particle (VLP) vaccine: Homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine 2013, 31, 4305-4313.
60. D'Aoust, M. A., Couture, M. M., Charland, N., Trépanier, S. et al., The production of hemagglutinin-based virus-like particles in plants: A rapid, efficient and safe response to pandemic influenza. Plant Biotechnol. J. 2010, 8, 607-619.
61. Jul-Larsen, Å., Madhun, A. S., Brokstad, K. A., Montomoli, E. et al., The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants. Hum. Vaccin. Immunother. 2012, 8, 653-661.
62. Aguilar-Yáñez, J. M., Portillo-Lara, R., Mendoza-Ochoa, G. I., García-Echauri, S. A. et al., An influenza A/H1N1/2009 hemagglutinin vaccine produced in Escherichia coli. PLoS One 2010, 5, e11694.
63. Taylor, D. N., Treanor, J. J., Sheldon, E. A., Johnson, C. et al., Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine 2012, 30, 5761-5769.
64. Del Giudice, G., Rappuoli, R., Inactivated and adjuvanted influenza vaccines. Curr. Top. Microbiol. Immunol. 2015, 386, 151-180.
65. Krammer, F., Cox, R. J., The emergence of H7N9 viruses: a chance to redefine correlates of protection for influenza virus vaccines. Expert Rev. Vaccines 2013, 12, 1369-1372.
66. Wei, C. J., Boyington, J. C., McTamney, P. M., Kong, W. P. et al., Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010, 329, 1060-1064.
67. Ledgerwood, J. E., Zephir, K., Hu, Z., Wei, C. J. et al., Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J. Infect. Dis. 2013, 208, 418-422.
68. Talaat, K. R., Luke, C. J., Khurana, S., Manischewitz, J. et al., A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response. J. Infect. Dis. 2014, 209, 1860-1869.
69. Krammer, F., Palese, P., Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr. Opin. Virol. 2013, 3, 521-530.
70. Krammer, F., Pica, N., Hai, R., Margine, I., Palese, P., Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 2013, 87, 6542-6550.
71. Gerdil, C., The annual production cycle for influenza vaccine. Vaccine 2003, 21, 1776-1779.
72. Okuno, Y., Isegawa, Y., Sasao, F., Ueda, S., A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol. 1993, 67, 2552-2558.
73. Wang, T. T., Tan, G. S., Hai, R., Pica, N. et al., Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog. 2010, 6, e1000796.
74. Tan, G. S., Krammer, F., Eggink, D., Kongchanagul, A. et al., A pan-h1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J. Virol. 2012, 86, 6179-6188.
75. Sui, J., Hwang, W. C., Perez, S., Wei, G. et al., Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 2009, 16, 265-273.
76. Ekiert, D. C., Bhabha, G., Elsliger, M. A., Friesen, R. H. et al., Antibody recognition of a highly conserved influenza virus epitope. Science 2009, 324, 246-251.
77. Friesen, R. H., Lee, P. S., Stoop, E. J., Hoffman, R. M. et al., A common solution to group 2 influenza virus neutralization. Proc. Natl. Acad. Sci. USA 2014, 111, 445-450.
78. Ekiert, D. C., Friesen, R. H., Bhabha, G., Kwaks, T. et al., A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011, 333, 843-850.
79. Dreyfus, C., Laursen, N. S., Kwaks, T., Zuijdgeest, D. et al., Highly conserved protective epitopes on influenza B viruses. Science 2012, 337, 1343-1348.
80. Corti, D., Voss, J., Gamblin, S. J., Codoni, G. et al., A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011, 333, 850-856.
81. Tan, G. S., Lee, P. S., Hoffman, R. M., Mazel-Sanchez, B. et al., Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza a virus hemagglutinin. J. Virol. 2014, 88, 13580-13592.
82. Terajima, M., Cruz, J., Co, M. D., Lee, J. H. et al., Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies. J. Virol. 2011, 85, 13463-13467.
83. Dilillo, D. J., Tan, G. S., Palese, P., Ravetch, J. V., Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat. Med. 2014, 20, 143-151.
84. Krammer, F., Hai, R., Yondola, M., Tan, G. S. et al., Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J. Virol. 2014, 88, 3432-3442.
85. Friesen, R. H., Koudstaal, W., Koldijk, M. H., Weverling, G. J. et al., New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS One 2010, 5, e9106.
86. Neirynck, S., Deroo, T., Saelens, X., Vanlandschoot, P. et al., A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 1999, 5, 1157-1163.
87. El Bakkouri, K., Descamps, F., De Filette, M., Smet, A. et al., Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J. Immunol. 2011, 186, 1022-1031.
88. Schotsaert, M., De Filette, M., Fiers, W., Saelens, X., Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev. Vaccines 2009, 8, 499-508.
89. Hillaire, M. L., Osterhaus, A. D., Rimmelzwaan, G. F., Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. J. Biomed. Biotechnol. 2011, 2011, 939860.
90. Krammer, F., Palese, P., Universal influenza virus vaccines: need for clinical trials. Nat. Immunol. 2014, 15, 3-5.
91. Hai, R., Krammer, F., Tan, G. S., Pica, N. et al., Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J. Virol. 2012, 86, 5774-5781.
92. Margine, I., Krammer, F., Hai, R., Heaton, N. S. et al., Hemagglutinin Stalk-Based Universal Vaccine Constructs Protect against Group 2 Influenza A Viruses. J. Virol. 2013, 87, 10435-10446.
93. Krammer, F., Margine, I., Hai, R., Flood, A. et al., H3 Stalk-Based Chimeric Hemagglutinin Influenza Virus Constructs Protect Mice from H7N9 Challenge. J. Virol. 2014, 88, 2340-2343.
94. Krammer, F., Jul-Larsen, A., Margine, I., Hirsh, A. et al., An H7N1 Influenza Virus Vaccine Induces Broadly Reactive Antibody Responses against H7N9 in Humans. Clin. Vaccine Immunol. 2014, 21, 1153-1163.
95. Wrammert, J., Koutsonanos, D., Li, G. M., Edupuganti, S. et al., Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 2011, 208, 181-193.
96. Li, G. M., Chiu, C., Wrammert, J., McCausland, M. et al., Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc. Natl. Acad. Sci. USA 2012, 109, 9047-9052.
97. Pica, N., Hai, R., Krammer, F., Wang, T. T. et al., Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc. Natl. Acad. Sci. USA 2012, 109, 2573-2578.
98. Nachbagauer, R., Wohlbold, T. J., Hirsh, A., Hai, R. et al., Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J. Virol. 2014, 88, 13260-13268.
99. Ellebedy, A. H., Krammer, F., Li, G. M., Miller, M. S. et al., Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc. Natl. Acad. Sci. USA 2014, 111, 13133-13138.
100. Steel, J., Lowen, A. C., T, T. W., Yondola, M. et al., Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 2010, 1, 1-9.
101. Bommakanti, G., Citron, M. P., Hepler, R. W., Callahan, C. et al., Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc. Natl. Acad. Sci. USA 2010, 107, 13701-13706.
102. Bommakanti, G., Lu, X., Citron, M. P., Najar, T. A. et al., Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge. J. Virol. 2012, 86, 13434-13444.
103. Lu, Y., Welsh, J. P., Swartz, J. R., Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines. Proc. Natl. Acad. Sci. USA 2014, 111, 125-130.
104. Mallajosyula, V. V., Citron, M., Ferrara, F., Lu, X. et al., Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc. Natl. Acad. Sci. USA 2014, 111, E2514-2523.
105. Graves, P. N., Schulman, J. L., Young, J. F., Palese, P., Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants. Virology 1983, 126, 106-116.
106. Kirchenbaum, G. A., Ross, T. M., Eliciting broadly protective antibody responses against influenza. Curr. Opin. Immunol. 2014, 28, 71-76.
107. Giles, B. M., Ross, T. M., Computationally optimized antigens to overcome influenza viral diversity. Expert Rev. Vaccines 2012, 11, 267-269.
108. Giles, B. M., Bissel, S. J., Dealmeida, D. R., Wiley, C. A., Ross, T. M., Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines. Clin. Vaccine Immunol. 2012, 19, 128-139.
109. Giles, B. M., Ross, T. M., A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine 2011, 29, 3043-3054.
110. Giles, B. M., Crevar, C. J., Carter, D. M., Bissel, S. J. et al., A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection. J. Infect. Dis. 2012, 205, 1562-1570.
111. Huleatt, J., Nakaar, V., Desai, P., Huang, Y. et al., Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26, 201-214.
112. Wang, L., Hess, A., Chang, T. Z., Wang, Y. C. et al., Nanoclusters self-assembled from conformation-stabilized influenza M2e as broadly cross-protective influenza vaccines. Nanomedicine 2014, 10, 473-482.
113. Lillie, P. J., Berthoud, T. K., Powell, T. J., Lambe, T. et al., Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin. Infect. Dis. 2012, 55, 19-25.
114. Berthoud, T. K., Hamill, M., Lillie, P. J., Hwenda, L. et al., Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin. Infect. Dis. 2011, 52, 1-7.
115. Antrobus, R. D., Berthoud, T. K., Mullarkey, C. E., Hoschler, K. et al., Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses. Mol. Ther. 2014, 22, 233-238.
116. Lambe, T., Carey, J. B., Li, Y., Spencer, A. J. et al., Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1. Sci. Rep. 2013, 3, 1443.
117. Wang, T. T., Tan, G. S., Hai, R., Pica, N. et al., Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc. Natl. Acad. Sci. USA 2010, 107, 18979-18984.
118. Staneková, Z., Varecková, E., Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol. J. 2010, 7, 351.
119. Staneková, Z., Király, J., Stropkovská, A., Mikušková, T. et al., Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein. Acta Virol. 2011, 55, 61-67.
120. Kanekiyo, M., Wei, C. J., Yassine, H. M., McTamney, P. M. et al., Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 2013, 499, 102-106.
121. Schneemann, A., Speir, J. A., Tan, G. S., Khayat, R. et al., A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin. J. Virol. 2012, 86, 11686-11697.
122. Atsmon, J., Kate-Ilovitz, E., Shaikevich, D., Singer, Y. et al., Safety and immunogenicity of multimeric-001 - a novel universal influenza vaccine. J. Clin. Immunol. 2012, 32, 595-603.
123. Wohlbold, T. J., Krammer, F., In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen. Viruses 2014, 6, 2465-2494.
124. Johansson, B. E., Moran, T. M., Kilbourne, E. D., Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins. Proc. Natl. Acad. Sci. USA 1987, 84, 6869-6873.
125. Johansson, B. E., Kilbourne, E. D., Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition. J. Virol. 1993, 67, 5721-5723.
126. Couch, R. B., Kasel, J. A., Gerin, J. L., Schulman, J. L., Kilbourne, E. D., Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J. Infect. Dis. 1974, 129, 411-420.
127. Johansson, B. E., Grajower, B., Kilbourne, E. D., Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice. Vaccine 1993, 11, 1037-1039.
128. Kilbourne, E. D., Couch, R. B., Kasel, J. A., Keitel, W. A. et al., Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine 1995, 13, 1799-1803.
129. Johansson, B. E., Kilbourne, E. D., Immunization with purified N1 and N2 influenza virus neuraminidases demonstrates cross-reactivity without antigenic competition. Proc. Natl. Acad. Sci. USA 1994, 91, 2358-2361.
130. Kilbourne, E. D., Cerini, C. P., Khan, M. W., Mitchell, J. W., Ogra, P. L., Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. J. Immunol. 1987, 138, 3010-3013.
131. Sandbulte, M. R., Eichelberger, M. C., Analyzing swine sera for functional antibody titers against influenza A neuraminidase proteins using an enzyme-linked lectin assay (ELLA). Methods Mol. Biol. 2014, 1161, 337-345.
132. Sultana, I., Yang, K., Getie-Kebtie, M., Couzens, L. et al., Stability of neuraminidase in inactivated influenza vaccines. Vaccine 2014, 32, 2225-2230.
133. Doyle, T. M., Li, C., Bucher, D. J., Hashem, A. M. et al., A monoclonal antibody targeting a highly conserved epitope in influenza B neuraminidase provides protection against drug resistant strains. Biochem. Biophys. Res. Commun. 2013, 441, 226-229.
134. Doyle, T. M., Hashem, A. M., Li, C., Van Domselaar, G. et al., Universal anti-neuraminidase antibody inhibiting all influenza A subtypes. Antiviral Res. 2013, 100, 567-574.
135. Chen, Z., Kim, L., Subbarao, K., Jin, H., The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets. Vaccine 2012, 30, 2516-2522.
136. Wan, H., Gao, J., Xu, K., Chen, H. et al., Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses. J. Virol. 2013, 87, 9290-9300.
137. Easterbrook, J. D., Schwartzman, L. M., Gao, J., Kash, J. C. et al., Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice. Virology 2012, 432, 39-44.
138. Yang, H., Qiao, C., Tang, X., Chen, Y. et al., Human infection from avian-like influenza A (H1N1) viruses in pigs, China. Emerg. Infect. Dis. 2012, 18, 1144-1146.
139. Wang, D. Y., Qi, S. X., Li, X. Y., Guo, J. F. et al., Human infection with Eurasian avian-like influenza A(H1N1) virus, China. Emerg. Infect. Dis. 2013, 19, 1709-1711.
140. Lopez-Martinez, I., Balish, A., Barrera-Badillo, G., Jones, J. et al., Highly pathogenic avian influenza A(H7N3) virus in poultry workers, Mexico, 2012. Emerg. Infect. Dis. 2013, 19, 1531-1534.
141. Arzey, G. G., Kirkland, P. D., Arzey, K. E., Frost, M. et al., Influenza virus A (H10N7) in chickens and poultry abattoir workers, Australia. Emerg. Infect. Dis. 2012, 18, 814-816.